An iodine prophylaxis medicine in case of radioactive exposure has appeared in pharmacies

The company has reported that the new medicine Potassium Iodide-125-Darnitsa* will appear in the domestic pharmacies in late May. It can be purchased without a prescription. This medicine was released and registered as soon as possible, taking into account all the challenges regarding the potential radiation hazard. Darnitsa Pharmaceutical Company continues to cooperate actively with the Ministry of Health of Ukraine and the National Security and Defence Council of Ukraine regarding the protection of Ukrainians from radiation.

The medicine was developed in accordance with the regulations of the Ministry of Health on iodine prophylaxis in the event of a radiation exposure. Potassium iodide is used to protect the thyroid gland from the accumulation of radiation. The risk of radiation thyroid injury can be reduced or even prevented with the timely use of iodine prophylaxis. The prophylactic dose of potassium iodide should be taken only after the official radioactive warning and notification of the need for iodine prophylaxis.

As previously reported, Darnitsa donated 5.25 million doses of the medicine worth UAH 69 million to the Public Health Centre of the Ministry of Health of Ukraine.

Generally, to protect Ukrainians, Darnitsa produced 8.2 million doses of potassium iodide that makes the iodine prophylaxis possible for more than 8 million people if necessary.

Reference

PJSC pharmaceutical company Darnitsa was founded in 1930. Since 1998, Darnitsa has been the leader in Ukraine as for drug production in physical terms. Strategic areas of products portfolio development include cardiology, neurology, and pain management.

* the dietary supplement POTASSIUM IODIDE-125-DARNITSA, TU U 10.8-00481212-003:2022

The information must be exclusively distributed in specialized publications intended for medical institutions and doctors